Document Type : Hypothesis
Authors
1 Iran university of medical scinces
2 Department of cellular and molecular biology, facility of science , Islamic azad university of karaj, Karaj , Iran
3 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
4 Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
Abstract
Keywords
Virus infection pandemic COVID-19, which is from the coronavirus family, is becoming a global concern and an emergency for public health in 2019 and 2020 [1, 2]. According to current evidence, coronavirus infection causes moderate respiratory tract disorder and also leads to cardiovascular dysfunction when in extreme cases of coronavirus family infections such as SARS (Severe Acute Respiratory Syndrome), Middle East respiratory syndrome coronavirus (MERS) and COVID-19 (coronavirus disease-19) death may occur because all these forms of coronavirus have long-term cardiovascular and respiratory sequelae. However, the exact mechanism of these lethal processes and the signaling pathway involved in the cardiovascular system remains uncertain, and unfortunately, not enough information is available in this regard [2-5]. According to some recent study, angiotensin-converting enzyme 2 (ACE2) is one of the key targets of infection with COVID-19 and can also be used as a host receptor for SARS and MERS [3, 6]. Considering the basic principle of the main mechanism of coronavirus family pathogenesis, all these types of viruses namely SARS, MERS and COVID-19 have used ACE2 (as their host receptor) and can enter their target cells, including pulmonary and cardiovascular cells, through this enzyme [7, 8]. It has been shown that the ACE 2 over-expression has increased the risk of coronavirus infection in certain populations and ethnicities [9, 10]. Although the data on the COVIID-19 infection process and the role of ACE2 in this process are less than the data on SARS and the MERS pathogenesis process, in a recent study, it has been indicated that human recombinant soluble ACE2 (hrsACE2) blocks COVID-19 growth and can significantly block early stages of COVID-19 infections [11]. The results of this study showed that ACE2 inhibition can block infection but would not discuss the role of ACE2 after infection and in reduction of patients’ mortality [11]. On the other hand, concerning the role of ACE2 in the mortality rate of animal models with SARS infection, it was found that in mice with ACE2-/-, which were knocked down by their ACE2 genes; being infected with SARS virus is less likely compared to the normal mice (wild type) while mortality rates have been increased and are more than the average [8, 12]. The aforementioned data suggest that these ACE2-/- animals are less likely to be infected with SARS and other forms of coronaviruses, but if they were infected, their mortality rate will be increased [8, 12]. Therefore, it can be inferred that ACE2 has a dual complicated role in reducing the risk and the probability of coronavirus infection while its absence increases mortality risk [8-10]. On the other hand, based on clinical evidence regarding COVID-19 infection in particular, it was shown that the mortality rate from COVID-19 infection was extremely high in the elderly and patients with underlying heart and respiratory disease [13, 14]. Seemingly, one of the main reasons for this increase in the mortality rate of such patients is the reduction of expression of ACE2 [15, 16]. ACE2, as a potent cardio-pulmonary protective protein, plays an important role in reducing the cardiovascular incident and can also cause modulation of respiratory system function and performance [17, 18]. Angiotensin-converting enzyme 2 (ACE2) induces angiotensin (1-7) [Ang-(1-7)] to be produced from angiotensin-2 (AngII). Several previous studies have shown that the ACE2-Ang-(1-7) axis has a significant function in regulating normal cardiovascular and respiratory physiology and can be targeted as novel therapeutic agents in cardiopulmonary diseases [17-19]. They have also shown that ACE2 can inhibit cell death in both cardiac and pulmonary systems which indicate that this protein can constrain apoptosis and autophagy-related signaling pathways and that this mechanism can prevent cell death in various organs [19-21]. Figure 1. shows an illustration of the role of ACE2 on the signaling pathway for apoptosis and autophagy, and its mechanism for cell death prevention in both cardiac and pulmonary systems. Based on the aforementioned studies on the essential and protective function of ACE2 in the inhibition of cell death, apoptosis, and autophagy in both cardiac and pulmonary systems, high-risk patients, such as elderly people and patients with respiratory and cardiovascular disease, were hypothesized.
The angiotensin-converting enzyme 2 (ACE2) induces angiotensin (1-7) [Ang-(1-7)] development of angiotensin-2 (AngII). Ang (1-7) causes AT2R, which is the angiotensin receptor type-2. On the other hand, it has been demonstrated that ACE-2/Ang (1-7)/Mas causes B-cell lymphoma 2 )Bcl-2(/Beclin1 or Bcl-2/Bax complex stability and inhibits autophagy and apoptosis in the cardio-respiratory system, respectively. Ang (1-7) can inhibit phosphorylation by the c-Jun N-terminal kinase (JNK). Apoptosis and autophagy are regulated by the complexes of Bcl-2/Beclin1 and Bcl-2/Bax. Bcl-2 is an anti-apoptotic protein that interacts with Beclin1 (the key protein involved in autophagy) and Bax (the main protein involved in autophagy) in an unphosphorylated form. The induction of Bcl-2 phosphorylation after indications of autophagy or apoptosis including dysfunction in the signaling pathway of ACE-2/Mas / Ang (1-7) occurs in patients with the underlying cardio-respiratory disease and activates JNK. It leads to the phosphorylation (inactivation) of Bcl-2 and dissociation of this protein from Beclin1 orBcl-2-associated X protein)Bax( and thus, it causes autophagy or apoptosis in the respiratory and cardiac tissue of the patients and increases their mortality rate. Some indirect evidence indicates that one of the key causes of increased mortality rates in high-risk patients with COVID-19 virus infection is the lower expression and inactivation of ACE-2/Mas / Ang (1-7) in the cardiovascular system, resulting in the activation of JNC / Bcl-2-Beclin1 or JNC / Bcl-2-Bax signaling pathway and the initiation of autophagy or apoptosis and also the death signal (Figure 1).
Figure 1: The role of ACE2 on the signaling pathway for apoptosis and autophagy, and its mechanism for cell death prevention in both cardiac and pulmonary systems (ACE-1: Angiotensin-converting enzyme -1; ACE-2: angiotensin-converting enzyme 2; Ang 1 and II: Angiotensin I and II, AT2R: Angiotensin Receptor Type 2; eNOS: endothelial Nitric Oxide Sythease; JNK; c-Jun N-terminal kinase; Bax: Bcl-2-associated X protein; Bcl-2: B-cell lymphoma 2.
The results show that infection with COVID-19 and other forms of coronaviruses has increased mortality rates and one of the key reasons of the increased mortality rates is a decrease in the expression of ACE2 and an increase in the apoptosis and autophagy cycle that occurred after this decrease in expression. It is also suggested that targeting and/or expression of ACE2 activity, and probably its downstream Ang (1-7)/ Mas axis in the respiratory and cardiovascular system can protect these systems and inhibit their denial and dysfunction, leading to the decrease in the mortality rates following COVID-19 infection and other types of coronaviruses. However, this therapeutic recommendation (activation of ACE2 or increasing its expression) is useful only after the incident of coronavirus infection and can be useful in protecting the cardiopulmonary system. Whereas, it cannot play a preventive role because increasing the expression of this enzyme will increase the prevalence of the disease. In fact, our therapeutic advice to increase the expression of ACE2 is a post-infection therapy approach and is not a preventive one.
Key words
COVID-19, ACE-2 / Ang (1-7) / Mas, Apoptosis, Autophagy
Acknowledgments
We thank all the colleagues, at Iran University of Medical Sciences, who helped us in presenting and preparing this hypothesis.
Authors’ contributions
Conception or design of the work; was done by Majid Motaghinejad.
Acquisition, analysis, or interpretation of literature for the work; was done by M AM and M Gh.
Drafting the paper, revising and final approval of the version was done by M M and S S.
Funding source
This paper is hypothesis and there is no specific financial source for it.
Conflict of Interest
None declared.
)